Piperlongumine (Synonyms: 荜茇酰胺; Piplartine)

目录号: HY-N2329 纯度: 99.87%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Piperlongumine 是一种生物碱，具有抗炎、抗菌、抗血管生成、抗氧化、抗肿瘤和抗糖尿病等活性。在肿瘤细胞中，Piperlongumine 能够诱导 ROS 和凋亡。Piperlongumine 具有抗心肌纤维化的作用，通过抑制 ERK1/2 信号通路抑制肌成纤维细胞的转化。Piperlongumin 可用于迁移体的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Piperlongumine Chemical Structure

CAS No. : 20069-09-4

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥302	In-stock
5 mg	￥275	In-stock
10 mg	￥500	In-stock
25 mg	￥750	In-stock
50 mg	￥1184	In-stock
100 mg	￥1775	In-stock
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

MCE 顾客使用本产品发表的 7 篇科研文献

•Original Article. 2022.

: Piperlongumine purchased from MCE. Usage Cited in: Original Article. 2022.; Piperlongumine (PL) affectes the expression of ferroptosis related proteins in OSCC cells. PL (6, 12, 24 h) increases the expression of DMT1 in OSCC cells, and decreases the expression of FTH1, SLC7A11 and GPX4.

Piperlongumine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 ERK 亚型特异性产品:

查看所有亚型

ERK ERK1 ERK2 ERK5 ERK8

生物活性
纯度 & 产品资料
参考文献

生物活性

Piperlongumine is a alkaloid^[1], possesses ant-inflammatory, antibacterial, antiangiogenic, antioxidant, antitumor, and antidiabetic activities^[2]. Piperlongumine induces ROS, and induces apoptosis in cancer cell lines^[1]. Piperlongumine shows anti-cardiac fibrosis activity, suppresses myofibroblast transformation via suppression of the ERK1/2 signaling pathway. Piperlongumin could be used in the study of migrasome^[2]^[3].

IC₅₀ & Target^[2]

ERK1

ERK2

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A-375	EC₅₀	6.17 μM Compound: piperlongumine	Antiproliferative activity against human A375 cells after 72 hrs by MTT assay Antiproliferative activity against human A375 cells after 72 hrs by MTT assay	[PMID: 25826398]
A549	ED₅₀	0.6 μg/mL Compound: 3	Cytotoxicity against human A549 cells after 6 days by MTT assay Cytotoxicity against human A549 cells after 6 days by MTT assay	[PMID: 2089124]
A549	IC₅₀	1.76 μM Compound: Piperlongumine	Inhibition of NF-kappaB in human A549 cells after 24 hrs by luciferase reporter gene assay Inhibition of NF-kappaB in human A549 cells after 24 hrs by luciferase reporter gene assay	[PMID: 27810594]
A549	IC₅₀	10 μM Compound: 1; PL	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 28159415]
A549	EC₅₀	12.2 μM Compound: piperlongumine	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 25826398]
A549	IC₅₀	15.22 μM Compound: 1	Antiproliferative activity against human A549 cells after 72 hrs in presence of ligustrazine by MTT assay Antiproliferative activity against human A549 cells after 72 hrs in presence of ligustrazine by MTT assay	[PMID: 29424539]
A549	IC₅₀	15.28 μM Compound: 1	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 29424539]
A549	IC₅₀	22.85 μM Compound: PL	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 24937186]
A549	IC₅₀	3.2 μM Compound: 1; PL	Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 32736231]
A549	IC₅₀	6.54 μM Compound: PL	Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
A549	IC₅₀	6.84 μM Compound: PL	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 28434764]
Bel-7402	IC₅₀	5.6 μM Compound: 1	Antiproliferative activity against human Bel-7402 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human Bel-7402 cells incubated for 24 hrs by MTT assay	[PMID: 34806369]
Bel-7402	IC₅₀	5.6 μM Compound: PL	Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33026807]
Bel7402/5-FU	IC₅₀	8.4 μM Compound: 1	Antiproliferative activity against human BEL-7402/5-FU cells incubated for 24 hrs by MTT assay Antiproliferative activity against human BEL-7402/5-FU cells incubated for 24 hrs by MTT assay	[PMID: 34806369]
Bel7402/5-FU	IC₅₀	8.4 μM Compound: PL	Cytotoxicity against human BEL-7402/5-FU cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human BEL-7402/5-FU cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33026807]
BHK-21	CC₅₀	40.14 μM Compound: Piplartine	Cytotoxicity against BHK21 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against BHK21 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31009908]
CMK	IC₅₀	1911 nM Compound: PL	Antiproliferative activity against Ara-C resistant human CMK cells after 72 hrs by MTT assay Antiproliferative activity against Ara-C resistant human CMK cells after 72 hrs by MTT assay	[PMID: 27505848]
CMK	IC₅₀	2815 nM Compound: PL	Antiproliferative activity against human CMK cells after 72 hrs by MTT assay Antiproliferative activity against human CMK cells after 72 hrs by MTT assay	[PMID: 27505848]
CMK	IC₅₀	421.8 nM Compound: PL	Antiproliferative activity against Ara-C resistant human CMK cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against Ara-C resistant human CMK cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
CMK	IC₅₀	612.7 nM Compound: PL	Antiproliferative activity against human CMK cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against human CMK cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
DU-145	GI₅₀	7.1 μM Compound: 1; PL	Growth inhibition of human DU145 cells after 48 hrs by WST-1 assay Growth inhibition of human DU145 cells after 48 hrs by WST-1 assay	[PMID: 29807795]
HaCaT	IC₅₀	16 μM Compound: PL, piplartine	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 24 hrs by MTT reduction assay Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 24 hrs by MTT reduction assay	[PMID: 25305718]
HaCaT	IC₅₀	3.03 μM Compound: 3	Cytotoxicity against human HaCaT assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HaCaT assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31400708]
HaCaT	EC₅₀	4.46 μM Compound: piperlongumine	Antiproliferative activity against human HaCaT cells after 72 hrs by MTT assay Antiproliferative activity against human HaCaT cells after 72 hrs by MTT assay	[PMID: 25826398]
HCT-116	EC₅₀	11.5 μM Compound: piperlongumine	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 25826398]
HCT-116	IC₅₀	6.04 μM Compound: PL	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 24937186]
HCT-116	IC₅₀	6.38 μM Compound: PL	Cytotoxicity against human HCT-116 incubated for 24 hrs by CCK-8 assay Cytotoxicity against human HCT-116 incubated for 24 hrs by CCK-8 assay	[PMID: 35696861]
HCT-116	IC₅₀	6.9 μM Compound: PL	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33026807]
HCT-116	IC₅₀	7.34 μM Compound: PL	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 28434764]
HCT-116	IC₅₀	8.13 μM Compound: 1	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 29424539]
HCT-116	IC₅₀	8.13 μM Compound: Piperlongumine	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 28686911]
HCT-116	IC₅₀	8.17 μM Compound: 1	Antiproliferative activity against human HCT116 cells after 72 hrs in presence of ligustrazine by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs in presence of ligustrazine by MTT assay	[PMID: 29424539]
HCT-116	IC₅₀	9.2 μM Compound: 1; PL	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 28159415]
HCT-8	IC₅₀	4.1 μM Compound: 1	Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 29424539]
HCT-8	IC₅₀	4.1 μM Compound: Piperlongumine	Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 28686911]
HeLa	IC₅₀	16.3 μM Compound: 8	Growth inhibition of human HeLa cells measured after 48 hrs by MTT assay Growth inhibition of human HeLa cells measured after 48 hrs by MTT assay	[PMID: 34669417]
Hep 3B2	IC₅₀	69.46 μM Compound: PL	Cytotoxicity against human Hep3B cells after 72 hrs by MTT assay Cytotoxicity against human Hep3B cells after 72 hrs by MTT assay	[PMID: 24937186]
HepG2	IC₅₀	6.8 μM Compound: 1	Antiproliferative activity against human HepG2 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 24 hrs by MTT assay	[PMID: 34806369]
HepG2	IC₅₀	6.8 μM Compound: PL	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33026807]
HepG2	IC₅₀	8.9 μM Compound: 1; PL	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 28159415]
HFF-1	EC₅₀	13.1 μM Compound: piperlongumine	Antiproliferative activity against HFF1 cells after 72 hrs by MTT assay Antiproliferative activity against HFF1 cells after 72 hrs by MTT assay	[PMID: 25826398]
HGC-27	IC₅₀	8.1 μM Compound: PL	Cytotoxicity against human HGC-27 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HGC-27 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33026807]
HGC-27	IC₅₀	8.2 μM Compound: 1	Antiproliferative activity against human HGC-27 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human HGC-27 cells incubated for 24 hrs by MTT assay	[PMID: 34806369]
HL-60	IC₅₀	1128 nM Compound: PL	Antiproliferative activity against Ara-C resistant human HL60 cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against Ara-C resistant human HL60 cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
HL-60	IC₅₀	1778 nM Compound: PL	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 27505848]
HL-60	IC₅₀	2250 nM Compound: PL	Antiproliferative activity against Ara-C resistant human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against Ara-C resistant human HL60 cells after 72 hrs by MTT assay	[PMID: 27505848]
HL-60	IC₅₀	529.2 nM Compound: PL	Antiproliferative activity against human HL60 cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
HT-1080	IC₅₀	3.43 μM Compound: PL	Cytotoxicity against human HT1080 cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human HT1080 cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
HT-29	ED₅₀	0.45 μg/mL Compound: 3	Cytotoxicity against human HT-29 cells after 6 days by MTT assay Cytotoxicity against human HT-29 cells after 6 days by MTT assay	[PMID: 2089124]
HT-29	IC₅₀	2.65 μM Compound: 1	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 29424539]
HT-29	IC₅₀	2.65 μM Compound: Piperlongumine	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 28686911]
HT-29	IC₅₀	5.49 μM Compound: PL	Cytotoxicity against human HT-29 cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human HT-29 cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
Jurkat	IC₅₀	1.4 μM Compound: 1; PL	Antiproliferative activity in human Jurkat cells assessed as cell viability after 48 hrs by alamarBlue assay Antiproliferative activity in human Jurkat cells assessed as cell viability after 48 hrs by alamarBlue assay	[PMID: 27689728]
Jurkat	IC₅₀	5 μM Compound: 1; PL	Cytotoxicity against human Jurkat cells after 24 hrs by MTT assay Cytotoxicity against human Jurkat cells after 24 hrs by MTT assay	[PMID: 27689728]
K562	IC₅₀	5.05 μM Compound: 1	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 29424539]
K562	IC₅₀	5.09 μM Compound: 1	Antiproliferative activity against human K562 cells after 72 hrs in presence of ligustrazine by MTT assay Antiproliferative activity against human K562 cells after 72 hrs in presence of ligustrazine by MTT assay	[PMID: 29424539]
KB	IC₅₀	1.67 μM Compound: 1; PL	Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay	[PMID: 32736231]
KB	ED₅₀	1.8 μg/mL Compound: 3	Cytotoxicity against human KB cells after 3 days by MTT assay Cytotoxicity against human KB cells after 3 days by MTT assay	[PMID: 2089124]
LNCaP	GI₅₀	> 10 μM Compound: 1; PL	Growth inhibition of human LNCAP cells after 24 to 48 hrs by WST-1 assay Growth inhibition of human LNCAP cells after 24 to 48 hrs by WST-1 assay	[PMID: 29807795]
LNCaP	GI₅₀	9.2 μM Compound: 1; PL	Growth inhibition of human LNCAP cells after 48 hrs by WST-1 assay Growth inhibition of human LNCAP cells after 48 hrs by WST-1 assay	[PMID: 29807795]
MCF-10A	EC₅₀	18.1 μM Compound: piperlongumine	Antiproliferative activity against human MCF10A cells after 72 hrs by MTT assay Antiproliferative activity against human MCF10A cells after 72 hrs by MTT assay	[PMID: 25826398]
MCF7	IC₅₀	1.2 μM Compound: 1; PL	Antiproliferative activity in human MCF7 cells assessed as cell viability after 48 hrs by alamarBlue assay Antiproliferative activity in human MCF7 cells assessed as cell viability after 48 hrs by alamarBlue assay	[PMID: 27689728]
MCF7	IC₅₀	4.4 μM Compound: 1; PL	Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay	[PMID: 32736231]
MCF7	IC₅₀	6.14 μM Compound: PL	Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
MCF7	IC₅₀	8 μM Compound: 1; PL	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 27689728]
MDA-MB-231	IC₅₀	10.6 μM Compound: PL	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 28434764]
MDA-MB-231	IC₅₀	3.72 μM Compound: 1; PL	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay	[PMID: 32736231]
MDA-MB-231	IC₅₀	8.46 μM Compound: PL	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 24937186]
MOLM-13	IC₅₀	1838 nM Compound: PL	Antiproliferative activity against human MOLM13 cells harboring wild type p53/FLT3-ITD mutant after 72 hrs by MTT assay Antiproliferative activity against human MOLM13 cells harboring wild type p53/FLT3-ITD mutant after 72 hrs by MTT assay	[PMID: 27505848]
MOLM-13	IC₅₀	934.5 nM Compound: PL	Antiproliferative activity against human MOLM13 cells harboring wild type p53/FLT3-ITD mutant after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against human MOLM13 cells harboring wild type p53/FLT3-ITD mutant after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
MRC5	IC₅₀	35.04 μM Compound: PL	Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay	[PMID: 24937186]
MRC5	IC₅₀	37 μM Compound: 1; PL	Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay	[PMID: 28159415]
MV4-11	IC₅₀	1439 nM Compound: PL	Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay	[PMID: 27505848]
MV4-11	IC₅₀	289.1 nM Compound: PL	Antiproliferative activity against human MV4-11 cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against human MV4-11 cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
OCI-AML-3	IC₅₀	1109 nM Compound: PL	Antiproliferative activity against human OCI-AML3 cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against human OCI-AML3 cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
OCI-AML-3	IC₅₀	1868 nM Compound: PL	Antiproliferative activity against human OCI-AML3 cells after 72 hrs by MTT assay Antiproliferative activity against human OCI-AML3 cells after 72 hrs by MTT assay	[PMID: 27505848]
P388	ED₅₀	0.9 μg/mL Compound: 3	Cytotoxicity against mouse P388 cells after 3 days by MTT assay Cytotoxicity against mouse P388 cells after 3 days by MTT assay	[PMID: 2089124]
PANC-1	IC₅₀	3.2 μM Compound: PL, piplartine	Cytotoxicity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT reduction assay Cytotoxicity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT reduction assay	[PMID: 25305718]
PC-3	GI₅₀	> 10 μM Compound: 1; PL	Growth inhibition of human PC3 cells after 24 to 48 hrs by WST-1 assay Growth inhibition of human PC3 cells after 24 to 48 hrs by WST-1 assay	[PMID: 29807795]
PC-3	GI₅₀	> 10 μM Compound: 1; PL	Growth inhibition of human PC3 cells after 48 hrs by WST-1 assay Growth inhibition of human PC3 cells after 48 hrs by WST-1 assay	[PMID: 29807795]
Platelet	IC₅₀	20.751 mM Compound: PL	Antiplatelet activity in rabbit plasma assessed as inhibition of arachidonic acid induced platelet aggregation by microplate reader analysis Antiplatelet activity in rabbit plasma assessed as inhibition of arachidonic acid induced platelet aggregation by microplate reader analysis	[PMID: 33930801]
Platelet	IC₅₀	6.71 mM Compound: PL	Antiplatelet activity in rabbit plasma assessed as inhibition of ADP induced platelet aggregation by microplate reader analysis Antiplatelet activity in rabbit plasma assessed as inhibition of ADP induced platelet aggregation by microplate reader analysis	[PMID: 33930801]
SAOS-2	IC₅₀	7.31 μM Compound: PL	Antiproliferative activity against human Saos2 cells after 72 hrs by MTT assay Antiproliferative activity against human Saos2 cells after 72 hrs by MTT assay	[PMID: 28434764]
SF-188	IC₅₀	3.9 μM Compound: PL	Cytotoxicity against human SF188 cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human SF188 cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
SH-SY5Y	IC₅₀	45.88 μM Compound: 3	Inhibition of TrxR in human SH-SY5Y cells using DTNB as substrate preincubated for 15 mins followed by substrate addition and measured for 20 mins by Ellman's method Inhibition of TrxR in human SH-SY5Y cells using DTNB as substrate preincubated for 15 mins followed by substrate addition and measured for 20 mins by Ellman's method	[PMID: 31400708]
SH-SY5Y	IC₅₀	5.94 μM Compound: 3	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31400708]
SK-BR-3	IC₅₀	4.04 μM Compound: PL	Cytotoxicity against human SKBR3 cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human SKBR3 cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
SK-HEP1	IC₅₀	13.3 μM Compound: PL	Antiproliferative activity against human SKHEP1 cells after 72 hrs by MTT assay Antiproliferative activity against human SKHEP1 cells after 72 hrs by MTT assay	[PMID: 28434764]
SK-MEL-2	EC₅₀	4.39 μM Compound: piperlongumine	Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by MTT assay Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by MTT assay	[PMID: 25826398]
SW-620	IC₅₀	4.62 μM Compound: 1	Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay	[PMID: 29424539]
T98G	IC₅₀	4.92 μM Compound: PL	Cytotoxicity against human T98G cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human T98G cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
U2OS	IC₅₀	9.49 μM Compound: PL	Antiproliferative activity against human U2OS cells after 72 hrs by MTT assay Antiproliferative activity against human U2OS cells after 72 hrs by MTT assay	[PMID: 28434764]
U-87MG ATCC	IC₅₀	16.15 μM Compound: 1	Antiproliferative activity against human U87MG cells after 72 hrs in presence of ligustrazine by MTT assay Antiproliferative activity against human U87MG cells after 72 hrs in presence of ligustrazine by MTT assay	[PMID: 29424539]
U-87MG ATCC	IC₅₀	17.34 μM Compound: 1	Antiproliferative activity against human U87MG cells after 72 hrs by MTT assay Antiproliferative activity against human U87MG cells after 72 hrs by MTT assay	[PMID: 29424539]
U-87MG ATCC	IC₅₀	7.18 μM Compound: 3	Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31400708]
U-937	IC₅₀	2174 nM Compound: PL	Antiproliferative activity against p53 null human U937 cells after 72 hrs by MTT assay Antiproliferative activity against p53 null human U937 cells after 72 hrs by MTT assay	[PMID: 27505848]
U-937	IC₅₀	767 nM Compound: PL	Antiproliferative activity against p53 null human U937 cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against p53 null human U937 cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
WI-38	IC₅₀	> 100 μM Compound: PL	Cytotoxicity against human W138 cells after 72 hrs by MTT assay Cytotoxicity against human W138 cells after 72 hrs by MTT assay	[PMID: 28434764]
WI-38	EC₅₀	20.3 μM Compound: PL	Senolytic activity against non-senescent human WI38 cells assessed as reduction in cell viability by propidium iodide staining based flow cytometry Senolytic activity against non-senescent human WI38 cells assessed as reduction in cell viability by propidium iodide staining based flow cytometry	[PMID: 29925484]
WI-38	IC₅₀	26.78 μM Compound: PL	Cytotoxicity against human WI38 cells after 72 hrs by MTT assay Cytotoxicity against human WI38 cells after 72 hrs by MTT assay	[PMID: 24937186]
WI-38	EC₅₀	8 μM Compound: PL	Senolytic activity against ionizing radiation induced human WI38 senescent cells assessed as reduction in cell viability by propidium iodide staining based flow cytometry Senolytic activity against ionizing radiation induced human WI38 senescent cells assessed as reduction in cell viability by propidium iodide staining based flow cytometry	[PMID: 29925484]
ZR-75-30	IC₅₀	5.86 μM Compound: PL	Cytotoxicity against human ZR75-30 cells after 72 hrs by MTT assay Cytotoxicity against human ZR75-30 cells after 72 hrs by MTT assay	[PMID: 24937186]

体外研究
(In Vitro)

Piplartine (5、10 和 15 μM) 在处理 24 和 48 小时后显著降低 786-O、SKBR3、Panc1、A549 和 L3.6pL 癌细胞的细胞增殖，在这些细胞系中诱导细胞凋亡和 ROS 在 5 和处理 3 或 9 小时后 10 μM^[1]。
Piplartine (5 或 10 μM) 诱导裂解的 PARP 并下调 Sp1、Sp3、Sp4 和 Sp 调节基因^[1]。
Piplartine (20 μM) 降低心脏成纤维细胞 (CF) 的活力。Piplartine (0-10 μM) 通过抑制 ERK1/2 信号通路抑制肌成纤维细胞转化^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Piperlongumine (30 mg/kg/天，腹腔注射，持续 3 周) 对携带 L3.6pL 细胞的无胸腺裸鼠表现出有效的抗肿瘤作用，且体重没有减轻^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

317.34

Formula

C₁₇H₁₉NO₅

CAS 号

20069-09-4

性状

固体

颜色

White to yellow

中文名称

荜茇酰胺

结构分类

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

细胞实验：

DMSO 中的溶解度 : 100 mg/mL (315.12 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.1512 mL	15.7560 mL	31.5119 mL
5 mM	0.6302 mL	3.1512 mL	6.3024 mL
10 mM	0.3151 mL	1.5756 mL	3.1512 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.88 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (7.88 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
方案三

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.55 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.87%

选择批次：

Data Sheet (644 KB) SDS (393 KB)

COA (264 KB) HNMR (258 KB) LCMS (94 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Karki K, et al. Piperlongumine Induces Reactive Oxygen Species (ROS)-Dependent Downregulation of Specificity Protein Transcription Factors. [Content Brief]

[2]. Wu X, e,t al. Piperlongumine inhibits angiotensin II-induced extracellular matrix expression in cardiac fibroblasts. J Cell Biochem. 2018 Dec;119(12):10358-10364 [Content Brief]

[3]. Yan Qin , et al. Pan-cancer analysis identifies migrasome-related genes as a potential immunotherapeutic target: A bulk omics research and single cell sequencing validation. Front Immunol. 2022 Nov 3;13:994828. [Content Brief]

Piperlongumine 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.1512 mL	15.7560 mL	31.5119 mL	78.7799 mL
	5 mM	0.6302 mL	3.1512 mL	6.3024 mL	15.7560 mL
	10 mM	0.3151 mL	1.5756 mL	3.1512 mL	7.8780 mL
	15 mM	0.2101 mL	1.0504 mL	2.1008 mL	5.2520 mL
	20 mM	0.1576 mL	0.7878 mL	1.5756 mL	3.9390 mL
	25 mM	0.1260 mL	0.6302 mL	1.2605 mL	3.1512 mL
	30 mM	0.1050 mL	0.5252 mL	1.0504 mL	2.6260 mL
	40 mM	0.0788 mL	0.3939 mL	0.7878 mL	1.9695 mL
	50 mM	0.0630 mL	0.3151 mL	0.6302 mL	1.5756 mL
	60 mM	0.0525 mL	0.2626 mL	0.5252 mL	1.3130 mL
	80 mM	0.0394 mL	0.1969 mL	0.3939 mL	0.9847 mL
	100 mM	0.0315 mL	0.1576 mL	0.3151 mL	0.7878 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Piperlongumine20069-09-4Piplartine荜茇酰胺ERKReactive Oxygen SpeciesAutophagyApoptosisBacterialFerroptosisExtracellular signal regulated kinasesInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

Piperlongumine (Synonyms: 荜茇酰胺; Piplartine)

Customer Review

MCE 顾客使用本产品发表的 7 篇科研文献

Piperlongumine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 ERK 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Piperlongumine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Piperlongumine (Synonyms: 荜茇酰胺; Piplartine)

Customer Review

Piperlongumine 相关抗体

MCE 顾客使用本产品发表的 7 篇科研文献

Piperlongumine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 ERK 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Piperlongumine 相关抗体:

摩尔计算器

稀释计算器

Piperlongumine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z